Skip to Main content Skip to Navigation
Journal articles

Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?

Abstract : The TWEAK/Fn14 pathway is now well-known for its involvement in the modulation of inflammation in various human autoimmune/chronic inflammatory diseases (AICID) including lupus, rheumatoid arthritis, and multiple sclerosis. A panel of data is now available concerning TWEAK expression in tissues or biological fluids of patients suffering from AICID, suggesting that it could be a promising biological marker in these diseases. Evidences from several teams support the hypothesis that blocking TWEAK/Fn14 pathway is an attractive new therapeutic lead in such diseases and clinical trials with anti-TWEAK-blocking antibodies are in progress. In this mini-review we discuss the potential use of TWEAK quantification in AICD management in routine practice and highlight the challenge of standardizing data collection to better estimate the clinical utility of such a biological parameter.
Document type :
Journal articles
Complete list of metadatas

Cited literature [32 references]  Display  Hide  Download

https://hal.archives-ouvertes.fr/hal-01718196
Contributor : Denis Becquet <>
Submitted on : Wednesday, April 18, 2018 - 10:25:36 AM
Last modification on : Wednesday, August 19, 2020 - 12:08:20 PM

File

fimmu-04-00489.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Daniel Bertin, Delphine Stephan, Michel Khrestchatisky, Sophie Desplat-Jégo. Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?. Frontiers in Immunology, Frontiers, 2013, 4, pp.489. ⟨10.3389/fimmu.2013.00489⟩. ⟨hal-01718196⟩

Share

Metrics

Record views

303

Files downloads

326